For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The price of Xeris Biopharma Holdings Inc (NASDAQ: XERS) closed at $7.36 in the last session, down -4.17% from day before closing price of $7.68. In other words, the price has decreased by -$4.17 from its previous closing price. On the day, 2.77 million shares were traded. XERS stock price reached its highest trading level at $7.79 during the session, while it also had its lowest trading level at $7.34.
Ratios:
We take a closer look at XERS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.24 and its Current Ratio is at 1.95.
On November 11, 2024, Piper Sandler Downgraded its rating to Neutral which previously was Overweight but kept the price unchanged to $3.
On March 28, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $5.Oppenheimer initiated its Outperform rating on March 28, 2024, with a $5 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 13 ’25 when JOHNSON JOHN sold 107,500 shares for $7.32 per share. The transaction valued at 786,459 led to the insider holds 833,483 shares of the business.
HALKUFF DAWN sold 42,500 shares of XERS for $309,226 on Aug 12 ’25. The Director now owns 115,000 shares after completing the transaction at $7.28 per share. On Aug 13 ’25, another insider, JOHN H JOHNSON, who serves as the Director of the company, bought 107,500 shares for $7.32 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XERS now has a Market Capitalization of 1188492800 and an Enterprise Value of 1386433536. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.83. Its current Enterprise Value per Revenue stands at 5.635 whereas that against EBITDA is 165.426.
Stock Price History:
The Beta on a monthly basis for XERS is 0.45, which has changed by 1.7259259 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, XERS has reached a high of $7.72, while it has fallen to a 52-week low of $2.48. The 50-Day Moving Average of the stock is 39.45%, while the 200-Day Moving Average is calculated to be 70.54%.
Shares Statistics:
According to the various share statistics, XERS traded on average about 2.46M shares per day over the past 3-months and 4830080 shares per day over the past 10 days. A total of 161.22M shares are outstanding, with a floating share count of 149.78M. Insiders hold about 7.23% of the company’s shares, while institutions hold 56.35% stake in the company. Shares short for XERS as of 1753920000 were 18222832 with a Short Ratio of 7.42, compared to 1751241600 on 19965518. Therefore, it implies a Short% of Shares Outstanding of 18222832 and a Short% of Float of 11.74.
Earnings Estimates
Xeris Biopharma Holdings Inc (XERS) is currently under the scrutiny of 2.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.04, with high estimates of $0.04 and low estimates of $0.03.
Analysts are recommending an EPS of between -$0.01 and -$0.01 for the fiscal current year, implying an average EPS of -$0.01. EPS for the following year is $0.16, with 2.0 analysts recommending between $0.31 and $0.0.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $73.61M. It ranges from a high estimate of $74.8M to a low estimate of $71.4M. As of the current estimate, Xeris Biopharma Holdings Inc’s year-ago sales were $54.27MFor the next quarter, 6 analysts are estimating revenue of $79.4M. There is a high estimate of $83.1M for the next quarter, whereas the lowest estimate is $75.2M.
A total of 6 analysts have provided revenue estimates for XERS’s current fiscal year. The highest revenue estimate was $288.3M, while the lowest revenue estimate was $271.7M, resulting in an average revenue estimate of $283.57M. In the same quarter a year ago, actual revenue was $203.07MBased on 6 analysts’ estimates, the company’s revenue will be $345.72M in the next fiscal year. The high estimate is $367.7M and the low estimate is $314.8M.
